Turn Therapeutics (TTRX) reported that an interim analysis of its adaptive Phase 2 trial of GX-03 for atopic dermatitis resulted in study design refinements and an expansion of the patient population. No efficacy or safety topline numbers were provided, but the update suggests improved trial execution and potential for more informative reads.
Turn Therapeutics (TTRX) reported that an interim analysis of its adaptive Phase 2 trial of GX-03 for atopic dermatitis resulted in study design refinements and an expansion of the patient population. No efficacy or safety topline numbers were provided, but the update suggests improved trial execution and potential for more informative reads.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
